A recent study published in New England Journal of Medicine aimed to see the effect of a new vaccine for herpes zooster virus in patients older than 50 years of age. This new vaccine differs that it is not a live attenuated vaccine, as the previous one, it is only composed of a subunit carrying the antigenic properties of the virus. The study included 15,411 patients over 50 years and were followed up for three years after receiving two doses of the vaccine. The study showed that this vaccine was superior than the live vaccine in efficacy even with age advancing and an additional benefit is its use in immunocompromised patients. Most common adverse effects were myalgia and pain at injection site, and they were tolerable. How often do you discuss vaccinations in you practice?
For more information please see Medscape
Image courtesy of [antpkr ]/FreeDigitalPhotos.net